La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Theriva Biologics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Theriva Biologics..

Theriva Biologics (AMEX:TOVX) Azioni, Catena delle Opzioni

Theriva Biologics

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Portland,,Or,,Usa,-,Jan,14,,2022:,Rumble,Mobile,App

News

Pre-Market Outlook

Markets

Trading Ideas

ASNS

OTEX

TOVX

XELB

Il mercato si anima con movimenti improvvisi su alcune quotazioni. Contratti e accordi strategici ridefiniscono il loro potenziale.

I titoli da tenere d&#39;occhio oggi: novità in arrivo per Actelis e XCel

Theriva Biologics Inc

Press Releases

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Health Care

Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

Financing

Theriva Biologics Announces Closing of $7.5 Million Public Offering

Earnings

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings

Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds

Aditxt

Apollomics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Azitra

Bone Biologics

BriaCell Therapeutics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

GRI Bio

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Oragenics

Onconetix

Polyrizon

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Revolution Medicines

Sunshine Biopharma

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Screenshot 2024-08-23 at 5.34.20 PM

Biotech

General

Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma

Screenshot 2024-07-31 at 5.25.33 PM

Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers

Screenshot 2024-07-08 at 2.14.39 PM

Disproportionate Rise In Pancreatic Cancer Among Young Women Highlights High Unmet Need To Find Safe, Effective Treatments – Is Hope On The Horizon?

Screenshot 2024-06-06 at 5.27.01 PM

Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer

Screenshot 2024-04-16 at 5.31.31 PM

Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers

Screenshot 2024-03-26 at 11.16.22 PM

Utilizing Common Viruses To Combat Dangerous Cancers – Hear From The Leaders Of This Biotech

Screenshot 2024-03-13 at 5.34.18 PM

How Theriva Biologics Is Using An Adenovirus To Develop A Novel Treatment For Pancreatic Cancer, As Well As Other Cancers With An Unmet Need

Screenshot 2024-03-05 at 6.31.45 PM

CADL

CGON

CLDI

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-28 at 6.54.06 PM

For The First Time The US Is Set To Hit 2 Million New Cancer Cases: Theriva Biologics Presents Novel Solutions To The Deadliest Cancers

Comments

Theriva Biologics

Theriva Biologics (TOVX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO